Krishnan Nandabalan - 10 Nov 2022 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Signature
/s/ Richard Steinhart, Attorney-in-Fact for Krishnan Nandabalan
Issuer symbol
BTAI
Transactions as of
10 Nov 2022
Transactions value $
-$875,400
Form type
4
Filing time
14 Nov 2022, 19:00:35 UTC
Previous filing
14 Feb 2022
Next filing
14 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise $11.3K +27.5K $0.41* 27.5K 10 Nov 2022 Direct
transaction BTAI Common Stock Sale -$412K -27.5K -100% $15.00* 0 10 Nov 2022 Direct F1, F2
transaction BTAI Common Stock Options Exercise $13.3K +32.6K $0.41* 32.6K 11 Nov 2022 Direct
transaction BTAI Common Stock Sale -$488K -32.6K -100% $15.00* 0 11 Nov 2022 Direct F1, F3
holding BTAI Common Stock 8.55M 10 Nov 2022 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Stock Options Options Exercise $0 -27.5K -5.79% $0.00 447K 10 Nov 2022 Common Stock 27.5K $0.41 Direct F5
transaction BTAI Stock Options Options Exercise $0 -32.6K -7.29% $0.00 414K 11 Nov 2022 Common Stock 32.6K $0.41 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.
F2 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4 These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
F5 The options are fully vested and exercisable